SCHEMBL5084174

SCHEMBL5084174

COc1cc(N)c2nc(C3C4CC5CC(C4)CC3(C(C)CCCN)C5)ccc2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.36
KDM4E B2RXH2 2/20 0.36
CASP1 P29466 2/20 0.36
ABCB11 O95342 1/20 0.36
ESR1 P03372 1/20 0.36
PGR P06401 1/20 0.36
ADRB2 P07550 1/20 0.36
CHRM2 P08172 1/20 0.36
ADRB1 P08588 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
NQO2 P16083 1/20 0.36
MAOA P21397 1/20 0.36
PTGS1 P23219 1/20 0.36
SLC6A2 P23975 1/20 0.36
MAOB P27338 1/20 0.36
PDE4A P27815 1/20 0.36
SLC6A4 P31645 1/20 0.36
SHMT2 P34897 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4729616 0.73 CYP2D6 (0.35) CYP1A2KDM4ESLC6A2SLC6A4SLC6A3
SCHEMBL6269582 0.69 KDM4E (0.46) CYP1A2KDM4ECASP1ABCB11ESR1
Hydrochloric Acid SCHEMBL6271964 0.68 ALDH1A1 (0.46) CYP1A2KDM4ECASP1ABCB11ESR1
SCHEMBL4729614 0.68 IDO1 (0.43) KDM4EPGRALDH1A1LMNA
SCHEMBL5080644 0.60 KDM4E (0.39) CYP1A2KDM4ECASP1ABCB11ESR1
SCHEMBL441572 0.59 NFKBIA (0.52) CYP1A2KDM4EHTR1AALDH1A1LMNA
SCHEMBL4728525 0.58 MAOA (0.70) CYP1A2KDM4ECASP1ABCB11ESR1
SCHEMBL11545623 0.58 NCF1 (0.39) CYP1A2KDM4EALDH1A1CYP3A4CYP2D6
SCHEMBL6404698 0.58 CYP1A2 (0.37) CYP1A2KDM4ECASP1ABCB11ESR1
SCHEMBL11690033 0.58 MEN1 (0.44) CYP1A2KDM4ENQO2PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
US-6979740-B2 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2005-12-27 US disclosed
EP-1606263-A1 RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS Council of Scientific and Industrial Research (IN) 2005-12-21 EP disclosed
WO-2004085402-A1 RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-10-07 WO disclosed
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents QDPR, SLC11A2, CYP2C8 CYP1A2 66/4885KDM4E 64/4885CASP1 343/4885
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN CYP1A2 4587/4885KDM4E 3242/4885CASP1 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.